Neurolymphomatosis (NL) is a rare manifestation of lymphoma confined to the peripheral nervous system that is poorly understood. It can be found in the cauda equina, but extraspinal disease can be underappreciated. The authors describe how extraspinal NL progresses to the cauda equina by perineural spread and the implications of this on timely and safe diagnostic options.
The authors used the Mayo Clinic medical records database to find cases of cauda equina NL with sufficient imaging to characterize the lumbosacral plexus diagnosed from tissue biopsy. Demographics (sex, age), clinical data (initial symptoms, cerebrospinal fluid, evidence of CNS involvement, biopsy location, primary or secondary disease), and imaging findings were reviewed.
Ten patients met inclusion and exclusion criteria, and only 2 of 10 patients presented with cauda equina symptoms at the time of biopsy, with 1 patient undergoing a cauda equina biopsy. Eight patients were diagnosed with diffuse large B-cell lymphoma, 1 with low-grade B-cell lymphoma, and 1 with mantle cell lymphoma. Isolated spinal nerve involvement was identified in 5 of 10 cases, providing compelling evidence regarding the pathophysiology of NL. The conus medullaris was not radiologically involved in any case. Lumbosacral plexus MRI was able to identify extraspinal disease and offered diagnostically useful biopsy targets. FDG PET/CT was relatively insensitive for detecting disease in the cauda equina but was helpful in identifying extraspinal NL.
The authors propose that perineural spread of extraspinal NL to infiltrate the cauda equina occurs in two phases. 1) There is proximal and distal spread along a peripheral nerve, with eventual spread to anatomically connected nerves via junction and branch points. 2) The tumor cells enter the spinal canal through corresponding neural foramina and propagate along the spinal nerves composing the cauda equina. To diffusely infiltrate the cauda equina, a third phase occurs in which tumor cells can spread circumdurally to the opposite side of the spinal canal and enter contralateral nerve roots extending proximally and distally. This spread of disease can lead to diffuse bilateral spinal nerve disease without diffuse leptomeningeal spread. Recognition of this phasic mechanism can lead to identification of safer extraspinal biopsy targets that could allow for greater functional recovery after appropriate treatment.
BourquePR, SampaioML, Warman-ChardonJ, Neurolymphomatosis of the lumbosacral plexus and its branches: case series and literature review. BMC Cancer. 2019;19(1):1149.10.1186/s12885-019-6365-y31775683)| false
MurthyNK, AmramiKK, SpinnerRJ. Circumdural extension of perineural spread leading to bilateral disease in neurolymphomatosis. Acta Neurochir (Wien). 2020;162(12):3197–3200.10.1007/s00701-020-04417-3)| false
PittmanM, TreeseS, ChenL, Utility of flow cytometry of cerebrospinal fluid as a screening tool in the diagnosis of central nervous system lymphoma. Arch Pathol Lab Med. 2013;137(11):1610–1618.10.5858/arpa.2012-0313-OA)| false
AkagiA, OnoK, HamaguchiT, Neurolymphomatosis exhibiting repeated exacerbation and remission in both the peripheral and central nervous systems. J Neurol Sci. 2014;345(1-2):267–268.2508278110.1016/j.jns.2014.07.038)| false
Quiñones-HinojosaA, FriedlanderRM, BoyerPJ, et al.Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg. 2000;92(1):165–169.
Quiñones-HinojosaA, FriedlanderRM, BoyerPJ, Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg. 2000;92(1):165–169.1061609710.3171/jns.2000.92.1.0165)| false
ZhengM, PerryAM, BiermanP, Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathology. 2017;37(6):509–516.10.1111/neup.1240528856744)| false
KhuranaA, NovoM, NowakowskiGS, Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021;5(5):1379–1387.3366129810.1182/bloodadvances.2020003666)| false